All In Biotech

Drug Trial Radar · NCT03509025

Follow-up Study for Participants Jointstem Clinical Trial

Open, Multicenter Follow-up Trial About Active Group of Phase IIb Clinical Trial of JOINTSTEM in Patients With Degenerative Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Feb 8, 2017

Primary completion

Dec 9, 2020

Study completion Dec 9, 2020

Sponsor

Lead sponsor
R-BioIndustry
Sponsor type
Industry
First posted
Apr 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a long term follow-up study to investigate the safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Knee Osteoarthritis.

Conditions

  • Knee Osteoarthritis

Interventions

  • JointstemDrug

    JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 60 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • KyungHee University Gangdong Hospital

    Seoul, South Korea

  • GangNam Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.